Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib
Authors:
- 22 March 2015
- journal article
- letter
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 54 (4) , 567-568
Abstract
To the Editor, Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3, and has been approved for the treatment of advanced r...Keywords
This publication has 5 references indexed in Scilit:
- Acute Aortic SyndromeCirculation, 2013
- Overview and Management of Cardiac Adverse Events Associated With Tyrosine Kinase InhibitorsThe Oncologist, 2013
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinomaAnnals of Oncology, 2009
- Acute aortic dissection during sorafenib-containing therapyAnnals of Oncology, 2009